AR035756A1 - Uso de carbamatos en la preparacion de medicamentos para la prevencion o tratamiento de trastornos neurodegenerativos - Google Patents

Uso de carbamatos en la preparacion de medicamentos para la prevencion o tratamiento de trastornos neurodegenerativos

Info

Publication number
AR035756A1
AR035756A1 ARP020100697A ARP020100697A AR035756A1 AR 035756 A1 AR035756 A1 AR 035756A1 AR P020100697 A ARP020100697 A AR P020100697A AR P020100697 A ARP020100697 A AR P020100697A AR 035756 A1 AR035756 A1 AR 035756A1
Authority
AR
Argentina
Prior art keywords
carbamates
preparation
group
neurodegenerative disorders
medicines
Prior art date
Application number
ARP020100697A
Other languages
English (en)
Spanish (es)
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of AR035756A1 publication Critical patent/AR035756A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
ARP020100697A 2001-02-27 2002-02-27 Uso de carbamatos en la preparacion de medicamentos para la prevencion o tratamiento de trastornos neurodegenerativos AR035756A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27168201P 2001-02-27 2001-02-27
US10/081,764 US20020165273A1 (en) 2001-02-27 2002-02-21 Carbamate compounds for use in preventing or treating neurodegenerative disorders

Publications (1)

Publication Number Publication Date
AR035756A1 true AR035756A1 (es) 2004-07-07

Family

ID=26765943

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020100697A AR035756A1 (es) 2001-02-27 2002-02-27 Uso de carbamatos en la preparacion de medicamentos para la prevencion o tratamiento de trastornos neurodegenerativos

Country Status (26)

Country Link
US (3) US20020165273A1 (enExample)
EP (1) EP1383489B1 (enExample)
JP (1) JP4276840B2 (enExample)
KR (1) KR100910928B1 (enExample)
CN (1) CN1235579C (enExample)
AR (1) AR035756A1 (enExample)
AT (1) ATE361745T1 (enExample)
BR (1) BR0207645A (enExample)
CA (1) CA2439295C (enExample)
CY (1) CY1106753T1 (enExample)
CZ (1) CZ301203B6 (enExample)
DE (1) DE60220043T2 (enExample)
DK (1) DK1383489T3 (enExample)
ES (1) ES2284845T3 (enExample)
HU (1) HUP0303264A3 (enExample)
IL (2) IL157591A0 (enExample)
MX (1) MXPA03007718A (enExample)
MY (1) MY138156A (enExample)
NO (1) NO20033798L (enExample)
NZ (1) NZ527990A (enExample)
PL (1) PL364680A1 (enExample)
PT (1) PT1383489E (enExample)
RS (1) RS51055B (enExample)
RU (1) RU2300373C2 (enExample)
TW (1) TWI312679B (enExample)
WO (1) WO2002067925A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2583087C (en) * 2003-09-19 2012-07-10 Galileo Pharmaceuticals, Inc. Chroman derivatives
DK1809273T3 (da) * 2004-09-16 2010-08-02 Janssen Pharmaceutica Nv Anvendelse af 2-phenyl-1,2-ethandiol-(di)carbamater til behandling af epileptogenese
MX2007004491A (es) * 2004-10-15 2007-08-08 Johnson & Johnson Compuestos de carbamato para utilizar en el tratamiento de padecimientos neurodegenerativos.
US20070021500A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods for neuroprotection
ES2385087T3 (es) * 2005-07-26 2012-07-18 Sk Biopharmaceuticals Co., Ltd Procedimientos para tratar trastornos relacionados con sustancias
US7632963B2 (en) * 2006-10-06 2009-12-15 Janssen Pharmaceutica Nv Crystal of (S)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate
JP2010508355A (ja) * 2006-10-30 2010-03-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 鬱病を処置する方法
EA200970435A1 (ru) * 2006-10-31 2009-10-30 Янссен Фармацевтика, Н. В. Лечение общих расстройств развития
KR101532823B1 (ko) * 2010-07-02 2015-07-03 (주)바이오팜솔루션즈 페닐 카바메이트 화합물 및 이를 포함하는 근육 이완제
US9018253B2 (en) 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
US20130060024A1 (en) * 2011-09-07 2013-03-07 Satori Pharmaceuticals, Inc. Compounds useful for treating neurodegenerative disorders
EP2797878B1 (en) 2011-12-27 2017-08-16 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compounds for use in preventing or treating stroke
CN105189450B (zh) * 2013-03-12 2019-09-13 比皮艾思药物研发有限公司 氨基甲酸苯酯化合物及包含该化合物的用于预防或治疗精神障碍的组合物
ES2998534T3 (en) * 2013-03-12 2025-02-20 Bio Pharm Solutions Co Ltd Phenyl carbamate compounds for use in preventing or treating pediatric epilesy
WO2017150903A1 (en) 2016-02-29 2017-09-08 Bio-Pharm Solutions Co., Ltd. Sulfamate derivative compounds, processes for preparing them and their uses
KR102635936B1 (ko) 2016-12-14 2024-02-13 에스케이바이오팜 주식회사 탈수초성 질환의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
JP7408643B2 (ja) * 2018-09-21 2024-01-05 エスケー バイオファーマスティカルズ カンパニー リミテッド カルバメート化合物及びそれを含む製剤の急性ストレス障害又は心的外傷後ストレス障害の予防、軽減又は治療のための使用
EP4204395A4 (en) * 2020-08-31 2024-08-07 Bio-Pharm Solutions Co., Ltd. Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease
EP4211125A4 (en) 2020-09-10 2024-10-02 Bio-Pharm Solutions Co., Ltd. SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3278380A (en) * 1962-02-06 1966-10-11 Armour Pharma Methods of calming employing diphenyl hydroxy carbamate compounds
US3265728A (en) * 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
US5474990A (en) * 1989-10-20 1995-12-12 Olney; John W. Barbiturates as safening agents in conjunction with NMDA antagonists
CN1109880A (zh) * 1994-02-03 1995-10-11 合成实验室公司 3-(2-氨基乙基)-4-[3-(三氟甲基)苯甲酰基]-3，4-二氢-2h-1，4-苯并噁嗪衍生物、制备及其应用
US5492930A (en) * 1994-04-25 1996-02-20 Schering Corporation Method and formulation for treating CNS disorders
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
US5728728A (en) * 1996-04-10 1998-03-17 Kozachuk; Walter E. Methods of providing neuroprotection
US6232434B1 (en) * 1996-08-02 2001-05-15 Duke University Medical Center Polymers for delivering nitric oxide in vivo
PT1401424E (pt) * 2001-02-27 2007-02-28 Ortho Mcneil Pharm Inc Compostos carbamato para utilização na prevenção ou tratamento de distúrbios psicóticos
JP2004527492A (ja) * 2001-02-27 2004-09-09 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 運動障害の予防もしくは治療における使用のためのカルバメート化合物
CA2439475C (en) * 2001-02-27 2010-05-18 Carlos R. Plata-Salaman Carbamate compounds for use in preventing or treating bipolar disorder

Also Published As

Publication number Publication date
RS67403A (sr) 2006-12-15
PL364680A1 (en) 2004-12-13
IL157591A (en) 2009-12-24
CA2439295C (en) 2010-05-25
HK1060516A1 (en) 2004-08-13
CZ301203B6 (cs) 2009-12-09
JP2004523555A (ja) 2004-08-05
BR0207645A (pt) 2004-12-28
MXPA03007718A (es) 2004-11-12
DE60220043D1 (de) 2007-06-21
IL157591A0 (en) 2004-03-28
RU2300373C2 (ru) 2007-06-10
CN1235579C (zh) 2006-01-11
HK1065486A1 (en) 2005-02-25
EP1383489B1 (en) 2007-05-09
JP4276840B2 (ja) 2009-06-10
CZ20032313A3 (cs) 2004-08-18
HUP0303264A3 (en) 2012-07-30
EP1383489A1 (en) 2004-01-28
HUP0303264A2 (hu) 2004-01-28
WO2002067925A1 (en) 2002-09-06
DE60220043T2 (de) 2008-01-10
KR100910928B1 (ko) 2009-08-06
US20040171679A1 (en) 2004-09-02
CY1106753T1 (el) 2012-05-23
NO20033798D0 (no) 2003-08-26
NO20033798L (no) 2003-09-26
CA2439295A1 (en) 2002-09-06
NZ527990A (en) 2006-01-27
CN1503667A (zh) 2004-06-09
RS51055B (sr) 2010-10-31
RU2003128982A (ru) 2005-03-10
MY138156A (en) 2009-04-30
DK1383489T3 (da) 2007-08-06
US20020165273A1 (en) 2002-11-07
US20090005442A1 (en) 2009-01-01
TWI312679B (en) 2009-08-01
PT1383489E (pt) 2007-06-21
KR20030076714A (ko) 2003-09-26
ATE361745T1 (de) 2007-06-15
ES2284845T3 (es) 2007-11-16

Similar Documents

Publication Publication Date Title
AR035756A1 (es) Uso de carbamatos en la preparacion de medicamentos para la prevencion o tratamiento de trastornos neurodegenerativos
AR033426A1 (es) Uso de compuestos carbamatos en la prevencion o el tratamiento de trastornos de movimiento
BG108650A (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
AR035532A1 (es) Diaminotiazoles, composiciones farmaceuticas que los comprenden, intermediarios para la preparacion de dichos compuestos, uso de dichos compuestos en la preparacion de medicamentos, y procesos para la preparacion de dichos compuestos
MY133370A (en) Carbamate compounds for use in preventing or treating bipolar disorders
BR0207644A (pt) Compostos de carbamato para uso na prevenção ou no tratamento de distúrbio bipolar
AR033427A1 (es) Uso de compuestos carbamatos en el tratamiento del dolor
PT1399144E (pt) Compostos carbamato para utilizacao na prevencao ou tratamento de disturbios de ansiedade
BRPI0520451A2 (pt) métodos para tratamento de distúrbios associados a substáncias quìmicas
AR032876A1 (es) Compuestos de carbamato para utilizar en la prevencion o tratamiento de los trastornos psicoticos
AR054550A1 (es) Metodos para tratar la epileptogenesis
BR0112713A (pt) "compostos de carbamato para uso na prevenção ou tratamento de dor neuropática e dor associada a cefaléia em cacho e hemicrânia
BR0211240A (pt) Compostos de carbamato para uso na prevenção ou tratamento de dor neuropática e dor associada à cefaléia em cacho e hemicrânia
BR0211244A (pt) Compostos de carbamato para uso na prevenção ou tratamento de dor neuropática e dor associada com cefaléia em salvas e enxaqueca
AR032907A1 (es) Uso de compuestos carbamatos para la prevencion o tratamiento de trastornos de ansiedad
AR035757A1 (es) Uso de carbamatos para la fabricacion de medicamentos para prevenir o tratar un trastorno bipolar
AR033428A1 (es) Compuestos carbamatos para su uso en la prevencion o tratamiento de trastornos bipolares
TH66556A (th) สารยับยั้งเมททัลโลโพรทีเนส สไพโร-ไพริมิดีน-2,4,6-ไตรโอน
AR034785A1 (es) Compuestos de carbamato para utilizarse en la prevencion o tratamiento de dolor neuropatico y dolor asociado con cefalea migranosa y cefalea acuminada
AR033545A1 (es) Uso de compuestos de carbamato para la fabricacion de medicamentos
AR034786A1 (es) Compuestos de carbamato para utilizarse en la prevencion o tratamiento de dolor neuropatico y dolor asociado con cefalea migranosa y cefalea acuminada

Legal Events

Date Code Title Description
FB Suspension of granting procedure